Sullivan Derek J, Moran Gary P, Pinjon Emmanuelle, Al-Mosaid Asmaa, Stokes Cheryl, Vaughan Claire, Coleman David C
Microbiology Research Unit, Department of Oral Medicine, Oral Surgery and Oral Pathology, Dublin Dental School and Hospital, University of Dublin, Trinity College, Dublin 2, Ireland.
FEMS Yeast Res. 2004 Jan;4(4-5):369-76. doi: 10.1016/S1567-1356(03)00240-X.
Candida dubliniensis is a pathogenic yeast species that was first identified as a distinct taxon in 1995. Epidemiological studies have shown that C. dubliniensis is prevalent throughout the world and that it is primarily associated with oral carriage and oropharyngeal infections in human immunodeficiency virus (HIV)-infected and acquired immune deficiency syndrome (AIDS) patients. However, unlike Candida albicans, C. dubliniensis is rarely found in the oral microflora of normal healthy individuals and is responsible for as few as 2% of cases of candidemia (compared to approximately 65% for C. albicans). The vast majority of C. dubliniensis isolates identified to date are susceptible to all of the commonly used antifungal agents, however, reduced susceptibility to azole drugs has been observed in clinical isolates and can be readily induced in vitro. The primary mechanism of fluconazole resistance in C. dubliniensis has been shown to be overexpression of the major facilitator efflux pump Mdr1p. It has also been observed that a large number of C. dubliniensis strains express a non-functional truncated form of Cdr1p, and it has been demonstrated that this protein does not play a significant role in fluconazole resistance in the majority of strains examined to date. Data from a limited number of infection models reflect findings from epidemiological studies and suggest that C. dubliniensis is less pathogenic than C. albicans. The reasons for the reduced virulence of C. dubliniensis are not clear as it has been shown that the two species express a similar range of virulence factors. However, although C. dubliniensis produces hyphae, it appears that the conditions and dynamics of induction may differ from those in C. albicans. In addition, C. dubliniensis is less tolerant of environmental stresses such as elevated temperature and NaCl and H(2)O(2) concentration, suggesting that C. albicans may have a competitive advantage when colonising and causing infection in the human body. It is our hypothesis that a genomic comparison between these two closely-related species will help to identify virulence factors responsible for the far greater virulence of C. albicans and possibly identify factors that are specifically implicated in either superficial or systemic candidal infections.
都柏林念珠菌是一种致病性酵母菌种,于1995年首次被鉴定为一个独特的分类单元。流行病学研究表明,都柏林念珠菌在全球范围内普遍存在,并且主要与人类免疫缺陷病毒(HIV)感染和获得性免疫缺陷综合征(AIDS)患者的口腔携带及口咽感染有关。然而,与白色念珠菌不同,都柏林念珠菌在正常健康个体的口腔微生物群中很少见,在念珠菌血症病例中所占比例仅为2%(相比之下,白色念珠菌约占65%)。迄今为止鉴定出的绝大多数都柏林念珠菌分离株对所有常用抗真菌药物敏感,然而,在临床分离株中已观察到对唑类药物的敏感性降低,并且在体外很容易诱导产生。都柏林念珠菌对氟康唑耐药的主要机制已证明是主要易化子外排泵Mdr1p的过度表达。还观察到大量都柏林念珠菌菌株表达一种无功能的截短形式的Cdr1p,并且已证明该蛋白在迄今为止检测的大多数菌株的氟康唑耐药中不发挥重要作用。来自有限数量感染模型的数据反映了流行病学研究的结果,并表明都柏林念珠菌的致病性低于白色念珠菌。都柏林念珠菌毒力降低的原因尚不清楚,因为已表明这两个菌种表达的毒力因子范围相似。然而,尽管都柏林念珠菌能产生菌丝,但诱导的条件和动态似乎与白色念珠菌不同。此外,都柏林念珠菌对高温、NaCl和H₂O₂浓度等环境压力的耐受性较低,这表明白色念珠菌在人体定植和引起感染时可能具有竞争优势。我们的假设是,对这两个密切相关菌种进行基因组比较将有助于确定导致白色念珠菌毒力更强的毒力因子,并可能确定与浅表或全身性念珠菌感染特别相关的因子。